AstraZeneca stock falls after FDA panel votes against new cancer drug

Shares of AstraZeneca turned lower Friday after U.S. regulatory advisors voted against approving its experimental cancer drug.

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.